Skip to main content
. Author manuscript; available in PMC: 2017 Oct 1.
Published in final edited form as: Ann Rheum Dis. 2015 Nov 6;75(10):1757–1762. doi: 10.1136/annrheumdis-2015-208001

Figure 4.

Figure 4

Serum type I interferon (IFN) activity measurements prior to and 4–6 weeks after starting tumour necrosis factor (TNF)-α inhibitor therapy. (A–C) Type I IFN, IFN-β and IFN-β/α, respectively, in patients with non-response. (D–F) Type I IFN, IFN-β and IFN-β/α, respectively, in patients with good or moderate response. Line indicates the median, error bars show the IQR, p value by Mann–Whitney U test.